@article{8b2668ddb3864ab49718008fda837c77,
title = "Randomized phase II study of nivolumab (N) alone versus with pegilodecakin (PEG) in combination with N in patients (pts) with post-platinum immunotherapy-naive stage IV non-small cell lung cancer (NSCLC) and no or low PD-L1 expression (CYPRESS 2).",
author = "Jotte, \{Robert M.\} and Goldschmidt, \{Jerome H.\} and Schneider, \{Jeffrey Gary\} and Shum, \{Merrill Kingman\} and David Berz and Seneviratne, \{Lasika C.\} and Socoteanu, \{Matei P.\} and Annie Hung and Hozak, \{Rebecca R.\} and Chao, \{Bo H.\} and Nemunaitis, \{John J.\}",
note = "e21744 Background: Nivolumab (N) is an immune checkpoint inhibitor (CPI) approved to treat post-platinum NSCLC as monotherapy. PEG in combination with N has demonstrated promising efficacy in NSCLC pts in a phase I trial (IVY; NCT02009449; Naing et al., 2019 Lancet Oncol), providing rationale for this randomized phase II trial (CYPRESS 2).",
year = "2020",
month = may,
day = "25",
doi = "10.1200/JCO.2020.38.15\_SUPPL.E21744",
language = "American English",
volume = "38",
journal = "Journal of Clinical Oncology",
}